Biologics in pediatric psoriasis

J Dermatol. 2023 Apr;50(4):415-421. doi: 10.1111/1346-8138.16702. Epub 2023 Jan 18.


Psoriasis is a chronic inflammatory skin disorder with a chronic relapsing course. Biologics have revolutionized the treatment of adult psoriasis with higher efficacy and favorable safety profile. Recently, more studies have focused on the use of biologics in pediatric psoriasis, and several biologics have been approved for use therein. This review is divided into two sections: the first part focuses on real-world studies on the use of biologics in pediatric psoriasis and the second part summarizes the findings of other clinical trials related to biologics in pediatric psoriasis. Case reports have been excluded from this review. Several biologics were used for treating pediatric psoriasis and the efficacy is encouraging. According to the studies included in this review, anti-IL-12/23 and anti-IL-17A for treating pediatric psoriasis might have a better efficacy than anti-TNF-α, but more data are needed.

Keywords: biologics; pediatric psoriasis; plaque psoriasis; real-world studies.

Publication types

  • Review

MeSH terms

  • Adult
  • Biological Products* / therapeutic use
  • Child
  • Chronic Disease
  • Humans
  • Interleukin-12
  • Psoriasis* / drug therapy
  • Tumor Necrosis Factor Inhibitors / therapeutic use
  • Tumor Necrosis Factor-alpha


  • Biological Products
  • Tumor Necrosis Factor Inhibitors
  • Interleukin-12
  • Tumor Necrosis Factor-alpha